Hainan Shuangcheng Pharmaceuticals Co Ltd

Hainan Shuangcheng Pharmaceuticals maintains a debt-to-equity ratio of 0.52, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium risk, with a current ratio of 0.67, suggesting that its current liabilities exceed its current assets. Free cash flow stands at 12.3 million CNY, while operating cash flow is 60.9 million CNY, indicating a positive but modest cash generation capacity. Profitability metrics show a return on equity (ROE) of 4.62% and a return on assets (ROA) of 2.31%, both below the typical thresholds for high-performing pharmaceutical firms. The company's operating income of 86.9 million CNY and net income of 19.04 million CNY reflect a relatively narrow margin structure, which may limit its ability to reinvest in R&D or expand operations. The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This concentration increases exposure to domestic regulatory and economic shifts. No segment-specific revenue breakdown is available, but the company operates as a single business unit focused on pharmaceuticals. Looking ahead, the company's revenue is expected to grow modestly, though no specific growth rate is provided in the outlook. Capital expenditures were negative at -43.27 million CNY, suggesting asset disposals or reduced investment in new facilities. The risk assessment highlights a key flag: net cash is negative after subtracting total debt, indicating potential liquidity constraints. No recent filings or transcripts are available in the source data to provide insight into management commentary or strategic shifts. The company's financial disclosures are limited to standard annual reporting, with no additional material events disclosed in the available data.